Altimmune stock fell on February 13, 2024, following publication of a report noting that Altimmune's GLP-1 drug had low tolerability and was unlikely to generate the partnership opportunities the company needed to succeed. Then, on April 29, market analyst Guggenheim noted that a partership looked "increasingly unlikely," again causing the stock to fall. The lawsuit alleges that the company overstated its prospects for finding a strategic partner for its GLP-1 drug.
Contact our attorneys for a no-cost case evaluation.